Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(175 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
−
Profiles published here have completed one of the [[QIBA Profile Stages]] of development and been approved by their [[Committees|Biomarker Committee]].
+
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. 
 +
 
 +
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
  
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 +
 +
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 +
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 +
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 +
 +
 +
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 +
 +
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]]
 +
 +
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]
 +
 +
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean.pdf|QIBA CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening]] ''2018.11.18''
 +
 +
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
 +
 +
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 +
 +
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
  
−
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Consensus Profiles===
 
−
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]
 
−
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
 
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
−
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2
 
  
−
*[[Media:QIBA_fMRI_Profile_1_PC.pdf| QIBA fMRI Profile 2017-06-19]] ''Public Comment to open on June 19, 2017''  
+
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
−
*[[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (Public Comment Form: http://tinyurl.com/y8dy2pc2)  ''Public Comment is open for 90 days - until September 15, 2017''  
+
 
−
* [[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (Public Comment Form: https://goo.gl/fkL6rB)  
+
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on EOB April 5th)
−
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'')
+
 
−
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]]
+
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] (open for public comment until EOB June 3rd)
−
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]]
+
 
 +
 
 +
'''[[Comment Resolutions]]''' are posted for '''Past Public Comments''' and '''Past Technical Confirmations''' .
 +
 
 +
 
 +
==Format for Citing Profiles==
 +
Cite QIBA Profile documents as:
 +
 
 +
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. QIBA, ''Date''. Available from: ''URL''
 +
 
 +
Example:
 +
 
 +
: QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance.  Version 1.1.  Profile Stage: Consensus. QIBA, June 30, 2017.  Available from: http://qibawiki.rsna.org/index.php/Profiles
  
 
==Statements of Endorsement==
 
==Statements of Endorsement==

Revision as of 19:06, 14 May 2019

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations .


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement


See Also

Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=14067"